Drug Target Review

APRIL 14, 2025

The antibiotic market has long faced significant barriers to innovation, with structural issues that make it difficult for new antibiotics to gain traction. As the demand for novel antibiotics remains limited due to the preference for cheaper generics, the market has struggled to incentivise much-needed breakthroughs.

Therapies 52

Therapies Marketing Drug Development Treatment 52

DrugBank

JUNE 18, 2025

Drug development is a complex and highly regulated process. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other global counterparts, set rigorous standards to ensure that drugs are safe, effective, and high-quality. Regulatory agencies, such as the U.S.

Drug Development 52

Drug Development Clinical Trials Compliance Drugs 52

BioPharma Drive: Drug Pricing

JULY 14, 2025

Published July 14, 2025 Ben Fidler Senior Editor post share post print email license Takeda reported positive results for oveporexton, a drug being developed for narcolepsy Type 1, on July 14, 2025. The drug, formerly known as TAK-861 but now called oveporexton, was evaluated in two Phase 3 studies in a main type of narcolepsy.

Drugs 188

Drugs Clinical Trials Therapies Licensing 188

SugarCone Biotech

JULY 6, 2025

It follows that HER3-targeting therapies have emerged as a class of anti-cancer treatments designed to treat various tumors that have developed resistance to EGFR or HER2-directed therapies or have emerged due to a NRG1 gene fusion. This is an active drug development landscape with a lot of recent news.

Drug Development 56

Drug Development Drugs Clinical Trials Therapies 56

BioPharma Drive: Drug Pricing

JUNE 11, 2025

Published June 11, 2025 Ben Fidler Senior Editor post share post print email license The FDA on June 11, 2025 approved Nuvation's Ibtrozi for ROS1-positive non-small cell lung cancer. In a research note on Wednesday, RBC Capital Markets analyst Leonid Timashev estimated peak yearly sales of the drug could reach nearly $640 million.

FDA 270

FDA Drugs Therapies Science 270

BioPharma Drive: Drug Pricing

JUNE 26, 2025

Published June 26, 2025 Gwendolyn Wu Senior reporter post share post print email license B cells, like those pictured above, malfunction in autoimmune disease. Vor Biopharma licensed a drug in June 2025 that targets proteins essential to B cell survival. and European drugmakers.

Disease 109

Disease Licensing Licensing Therapies 109

BioPharma Drive: Drug Pricing

JULY 10, 2025

Deep Dive Library Events Press Releases Topics Sign up Search Sign up Search Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy An article from Dive Brief Moderna COVID vaccine gets full approval for children The approval comes amid regulatory upheaval under HHS head Robert F. Kennedy Jr., Track funding rounds here.

Vaccine 226

Vaccine FDA Therapies Licensing 226

BioPharma Drive: Drug Pricing

JULY 10, 2025

Published July 10, 2025 Ben Fidler Senior Editor post share post print email license Soleno Therapeutics on July 10, 2025 announced preliminary sales for its new Prader-Willi Syndrome drug Vykat. Until Vykat came along, though, no drug therapies were specifically approved to curb the all-consuming hunger that hallmarks the condition.

Drugs 221

Drugs Licensing Licensing Therapies 221

BioPharma Drive: Drug Pricing

JULY 2, 2025

Deep Dive Library Events Press Releases Topics Sign up Search Sign up Search Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy An article from Dive Brief Organon drug for endometriosis falls short in mid-stage study Company executives had seen the drug as a potential multi-billion dollar opportunity in women’s health.

Clinical Trials 240

Clinical Trials Drugs Licensing Licensing 240

Drug Patent Watch

DECEMBER 18, 2024

Drug patent prosecution is a complex and critical process that can make or break the success of a new medication. As a business professional in the pharmaceutical industry, understanding and implementing effective strategies for drug patent prosecution can be the difference between market domination and missed opportunities.

Pharmaceuticals 96

Pharmaceuticals Drugs Drug Development Marketing 96

BioPharma Drive: Drug Pricing

JUNE 26, 2025

Published June 26, 2025 Ned Pagliarulo Lead Editor post share post print email license An Incyte researcher works in a laboratory. and sold [Karuna],” wrote RBC Capital Markets analyst Brian Abrahams, in a note to clients. On June 26, 2025, the company announced the replacement of longtime CEO Hervé Hoppenot with Bill Meury. “We

Licensing 117

Licensing Licensing Therapies Vaccine 117

BioPharma Drive: Drug Pricing

JUNE 27, 2025

Published June 27, 2025 Ned Pagliarulo Lead Editor post share post print email license Bristol Myers Squibb sells two CAR-T cell therapies for cancer. On June 26, 2025, the Food and Drug Administration eased some of the medicines' reporting requirements. Abecma and J&J’s Carvykti are used for multiple myeloma.

Therapies 178

Therapies FDA Treatment Licensing 178

Perficient: Drug Development

JUNE 2, 2025

But Sensei’s true value isnt limited to content operations, it’s the unified AI engine that quietly powers marketing intelligence, customer personalization, and even creative automation across Adobes enterprise ecosystem. This post takes a broader look at how Adobe Sensei connects data, creativity, and experiences, at scale.

Engineering 52

Engineering Production Licensing Licensing 52

The Pharma Data

NOVEMBER 30, 2020

Vivlion holds an exclusive license to Goethe University of Frankfurt’s proprietary 3Cs technology for the production of next generation 3Cs CRISPR/Cas gRNA libraries. Vivlion holds an exclusive license to Goethe University of Frankfurt’s proprietary 3Cs technology for the production of next generation 3Cs CRISPR/Cas gRNA libraries.

Licensing 52

Licensing Licensing Production Drug Development 52

ASPET

OCTOBER 12, 2023

To maintain cadence with looming threats in a prolonged field care environment, the broader medical countermeasure (MCM) enterprise must adopt new strategies for CBRN-addressing drug development. CBRN MCMs).

Therapies 100

Therapies Licensing Licensing FDA Approval 100

DrugBank

OCTOBER 4, 2024

This involves assessing the strength and breadth of patents, evaluating the potential for future patent challenges, and analyzing the value derived from licensing agreements and royalty streams. billion acquisition of Grail , a cancer-detection test developer.

Pharmaceuticals 98

Pharmaceuticals Pharmaceutical Companies Therapies Marketing 98

BioPharma Drive: Drug Pricing

JUNE 23, 2025

The black and gray market risks Ben warned about the proliferation of counterfeit GLP-1 drugs in unregulated markets, posing significant dangers to patients who might unknowingly use ineffective or harmful products. The balance is complex, as obesity carries its own serious health risks.

Treatment 130

Treatment Drugs Therapies FDA 130

Drug Target Review

APRIL 23, 2024

The process of drug discovery is lengthy, and it can take 2-5 years on average to reach the preclinical phase. 1 To overcome the bottleneck of synthesising compounds of interest and forming derivatives for lead optimisation, in silico methods are being increasingly used in drug discovery workflows to drive efficiency. billion by 2031.

Licensing 100

Licensing Licensing Drugs Drug Development 100

Perficient: Drug Development

JANUARY 19, 2024

If you want to reduce capital and operational expenditures, speed time to market, and improve scalability, elasticity, security, and compliance, you should consider moving your on-premises IBM Sterling application to IBM supported native SaaS or other cloud solutions which best suits your business.

Compliance 118

Compliance Marketing Licensing Licensing 118

Predictive Oncology

MARCH 17, 2023

Cancer Research Horizons to incorporate PEDAL into future drug discovery processes to enable drug development on a global scale 11 marketed drugs 2nd largest oncology out-licensor globally 150+ active licenses 160+ new drugs into early-phase clinical trials $647 million revenue from royalties & IP $2.8

Research 52

Research Clinical Trials Licensing Licensing 52

Predictive Oncology

MARCH 21, 2023

Pamela Bush of Predictive Oncology discuss the potential impact of their collaboration and how it can advance cancer drug development.

Research 52

Research Licensing Licensing Drugs 52

Perficient: Drug Development

SEPTEMBER 19, 2023

Increased Capabilities for Marketing Cloud and Commerce Cloud Salesforce introduced 26 generative AI capabilities between Marketing Cloud and Commerce Cloud, 14 of which are in GA now, with an additional 14 to arrive by the end of 2024.

Licensing 59

Licensing Licensing Production Marketing 59

LifeSciVC

JANUARY 16, 2024

These are incredible forecasts and CAGRs, which if we assume directionally correct, rely not only on steady growth for approved therapies but also a substantial success rate of, and continued investment in, the development pipeline. recent announcements from Merck and Sanofi for obesity and broader metabolic disease). Join the club.

Small Molecule 143

Small Molecule Trials Therapies Disease 143

Perficient: Drug Development

OCTOBER 27, 2023

Spartacus is an open-source JavaScript framework developed by SAP for building modern, responsive, and feature-rich e-commerce storefronts. The Composable Storefront emerged as an ideal solution for expedited market entry. This solution reduces time to market for SAP Commerce new implementations, upgrades, and migrations.

Compliance 105

Compliance Marketing Licensing Licensing 105

The Pharma Data

JUNE 30, 2021

Agreement includes commercializing biosimilar candidate of ophthalmology drug ranibizumab (Lucentis ® ) in Europe, Canada, Israel and global markets. Bioeq has in-licensed the exclusive global commercialization rights to FYB201 from the German biosimilar developer Formycon AG.

Biosimilars 52

Biosimilars International Licensing Licensing 52

Perficient: Drug Development

NOVEMBER 10, 2023

Depending on the size of the team and anticipated activity within a program, additional RDEs can also be provisioned, however, this may come at an additional licensing cost from Adobe. Creating an Rapid Development Environment The RDE can be provisioned with a Program via Cloud Manager in AEM as a Cloud Service.

Packaging 105

Packaging Licensing Licensing International 105

FDA Law Blog: Biosimilars

SEPTEMBER 18, 2024

That clause excludes those ingredients that were first marketed as drug ingredients. However, FDA’s interpretation creates that exact risk for a dietary supplement manufacturer who invests in development of a dietary supplement.

Production 59

Production FDA Licensing Licensing 59

LifeSciVC

JULY 17, 2024

By Mike Cloonan, Chief Executive Officer of Sionna Therapeutics, as part of the From The Trenches feature of LifeSciVC The drug development process in rare diseases is rife with challenges especially when companies target significant differentiation or first-in-class targets.

Clinical Research 79

Clinical Research Disease Research Clinical Trials 79

Crown Bioscience

MAY 4, 2021

Among the 180+ cancer drugs approved by the FDA since 1995, only 14 have been approved for pediatric use, with another 26 used off-label (i.e. used in a way that is not described in the license), and only three drugs have been approved exclusively for use in children.

Research 52

Research Pharmaceutical Companies Licensing Licensing 52

The Pharma Data

NOVEMBER 8, 2020

The Series B financing will be mainly used to conduct global clinical trials, research and development, and product in-licensing activities. Inmagene is a leading drug development company focused on immunology-related therapeutic areas. To date, Inmagene has raised over $40 million financing.

Clinical Trials 40

Clinical Trials Licensing Licensing Drug Development 40

Drug Target Review

AUGUST 9, 2024

Knowing and formulating the drug’s solubility, stability and particle size through design and addition of excipients is a continuous process throughout drug development. 1 Challenges in drug formulation Developing a successful drug formulation is fraught with challenges.

Science 59

Science Drugs Compliance Drug Development 59

Molecule Blog

JANUARY 9, 2023

IP-NFTs upgrade our legacy intellectual system by unifying IP (patents, legal), underlying data (through decentralized storage and access control), and economics (royalties, license fees, sales) into one programmable, transactable, digital unit. ‍ How will IP-NFTs enable drug development in the future?

Research 52

Research Licensing Licensing Science 52

The Pharma Data

JANUARY 25, 2021

Ambulero holds an exclusive license from the University of Miami to develop and commercialize research from the laboratories of Drs. As part of the investment, Ambulero and Orphinic formed a Polish subsidiary (Ambulero Sp. that will lead clinical testing of a novel gene therapy for a serious vascular disease in Europe.

Therapies 52

Therapies Disease Licensing Licensing 52

The Pharma Data

JUNE 28, 2021

The companies acquired by Bayer, Noria and PSMA Therapeutics, have exclusive world-wide rights to technology licensed from Weill Cornell Medicine (New York, NY, USA) and Johns Hopkins University (Baltimore, MD, USA). Noria was founded by Dr. John Babich, Chief, Radiopharmaceutical Sciences in Radiology at Weill Cornell Medicine.

Small Molecule 52

Small Molecule Licensing Licensing Therapies 52

Drug Target Review

OCTOBER 14, 2024

Wilkie’s background as a biochemist and his time at Merck, a leading pharmaceutical company, shaped his early understanding of drug development and business strategy. As someone who describes himself as an “enthusiastic sceptic,” Wilkie is cautious but hopeful about the potential of AI in drug development. “I

Science 52

Science Pharmaceutical Companies Drug Development Pharmaceuticals 52

Alta Sciences

DECEMBER 14, 2023

Regulatory Excellence - Licenses for Schedule I through IV drug substances. Clinical Supply Manufacturing Integration with our manufacturing team, ensuring flexibility and adaptability to meet the evolving needs of your studies throughout your drug development program or study. 24/7 monitoring of temperature and humidity.

Compounding Pharmacies 40

Compounding Pharmacies Pharmacy Clinical Pharmacology Clinical Supply 40

Perficient: Drug Development

SEPTEMBER 11, 2023

Usually, Sitecore Headless Services can be implemented using the current licensing model, providing a seamless transition for existing Sitecore users, however we have seen clients on perpetual licenses need to negotiate with Sitecore to add this capability to their license. XM Cloud is where Sitecore is innovating.

Licensing 52

Licensing Licensing Packaging Marketing 52